Stability Studies and Choice of VVM Category



Overview

- These slides are focused mainly on vaccines
- The principles involved in choice of a vaccine vial monitor (VVM) or more generically a timetemperature indicator (TTI) are the same
- The principle is fashioned from WHO guidelines and their established methodologies
- This process has been applied to monoclonal antibodies, hormones, small molecules, diagnostic test kits and other pharma products
- The final choice of TTI category (sensitivity) is up to the manufacturer

Goals of Stability Studies in Product Development


- Establish product stability characteristics:
 - The principles involved in choice of a vaccine vial monitor (VVM) or more generically a time-temperature indicator (TTI) are the same
 - The principle is fashioned from WHO guidelines and their established methodologies
 - This process has been applied to monoclonal antibodies, hormones, small molecules, diagnostic test kits and other pharma products
 - The final choice of VVM category (sensitivity) for WHO/UNICEF is decided by WHO
 - The final choice of VVM/TTI category for other uses is up to the manufacturer

From: WHO Informal Consultation on Scientific and Regulatory Considerations on Stability of Vaccines under a Controlled Temperature Chain

Dean Smith & Tong Wu, Ph.D., Health Canada 4 June 2013, PEI, Langen, Germany



Temperature Sensitivity of Vaccines (2015)



B. Schreiber, D. Chang Blanc, TechNet Bangkok 2015



Studies Supporting Product Licensure¹

Studies supporting product licensure include:

- Long term stability of bulk intermediate
- Long term stability of final container product
- Accelerated stability at conditions of handling, excursion, and use
- Release and manufacturing models
- Clinical support of specifications






Approaches to Stability Assessment²

Currently stability data are usually analyzed using a "single point" model, wherein any individual data point on a stability study must meet end expiry specifications

• This has also been called the "compliance model"




²W. Egan, T. Schofield, Biologicals 37 (2009) 379-386

Approaches to Stability Assessment (cont.)

Use of statistical models is scientifically correct, is recognized by the WHO Guidance, and represents the future of stability analysis

• This has also been called the "comprehensive model", or the "estimation model" or the "statistical model"




Adapted from T.L. Schofield, Biologicals 37 (2009) 387-396



Impact of CTC on Vaccine Stability Studies

Manufacturers will need to provide additional stability data to support CTC onlabel approval



Temptime

Improving Global Health

Accelerated Stability Studies for WHO Prequalification

Goal

• Accelerated stability data must be generated that allows the choice of the highest stability VVM category possible.

Rationale

• At elevated temperatures, the highest category VVM which reaches its end point before the vaccine stored at the same temperature becomes sub-potent should be chosen. This ensures that the product is still suitable to use while minimizes wastage through premature discard of vaccine that is still potent.



Characteristics That Define Vaccine Suitability

Type of characteristic	Compliance	Deviation
Mandatory	Pre-qualification process proceeds	Rejection of application for prequalification evaluation.
Critical*	Pre-qualification process proceeds	Referral to the PSPQ Standing Committee for review, discussion and recommendation. After consideration of the PSPQ Standing Committee advice, the vaccine may be accepted or rejected for pre-qualification evaluation.
Unique and innovative	Referral to the PSPQ Standing Committee for review, discussion and recommendation. After consideration of the PSPQ Standing Committee advice, the vaccine may be accepted or rejected for pre-qualification evaluation.	
Preferred	Pre-qualification evaluation proceeds.	

*VVM is a critical characteristic for vaccine prequalification



UNICEF/WHO Policies on Criticality of VVMs

2007 UNICEF/WHO Joint Policy Statement Urging Member States, Donor Agencies and NGOs to Include VVMs As Minimum Requirement for Purchase of Vaccine



WHO-UNICEF policy statement on the

implementation of vaccine vial monitors: The role of vaccine vial monitors in improving access to immunization

World Health Organization (WHC) and United Nations Children's Fund (UNICEF), Marking the 10 years of auccossful implementation of vaccine vial members (VVHo); References to the UNIX-ENCECE policy statement on the upon of vaccine vial monitors in memory and the UNIX-ENCECE policy statement on the upon of vaccine vial monitors in

Hereinegis the INVO-UNLOP policy determines on the up of Velocitie Automatics in minutabilities services (IREA/MASCH 30), Making up of velocities (Annohesis WH-0/X828)03, 141, Gating statute with second will monitors (IMEA/X888)23(5), MH-0-UNLOPE (Velocities attacted on the History velocities does numagement (IMEA/X888)23(5), MH-0-UNLOPE (Velocities)23(5), March 2000, 1990

Emphasizing the Glishal Immunization Vision and Strategy aiming to protect more people against more diseases by organizing the seach of immunization to every eligible person, including these in age pages beyond infancy, within a context in which immunization is high on every health agenda;

Determined to reach every mother and child for vaccination against section proventable divergence;

Nating the challenges in immunication service delivery especially in areas with weak or no tokic chain infrastructure;

Acknowledging with appreciation the dedication of health workers throughout the world to avercome challenges in reaching all mathers and children with life saving vaccines;

ecognizing the cosperation of wassing manufacturers in applying vacane vial members or IHD pregailitied vacane products;

Acknowledging that the VMV is the only tool among all time and temperature indicates that is available at all times - in the process of clocege, distribution and at the time the vaccine is administent - indicating whether the vaccine has been exposed to a candination of excessive temperature over times and whether it is likely to have been damaged,

Further noting that since its introduction in 1956 with anal pellio vaccine, the VMM has contributed to the success of national immunization days as well as to overcoming access problems is areas with week or no cold-chain intrastructure and reduction of vaccine vastage.


Appreciating the evidence produced by many field studies on the positive impact of the WM on field operations, both routine and supplemental;

Recognizing that the benefits of WMI in overcoming the calid chain challenges and reaching the hand-to-mach populations will not be realized if they are not available;

Nating The use of WMs to support policies for storage and administration of vecches outside the odd chain to reach infants in rural and remain areas, such as for the hepatitis 8 sections birth disce for newborns;

Streaming the need that health workers require a consistent supply of vaccine with WMs in order to be able to rely upon them as a look

2012 WHO Includes VVMs As Critical Characteristic for Vaccine Prequalification



Vaccine Vial V Monitor (VVM)

Vaccines Proof of feasibility and intent to apply a VVM to the proposed vaccine, as defined below.

- The vaccine presented for prequalification presents data confirming that it has a thermostability profile that will enable it to be matched to a current WHOapproved VVM type (VVM2, VVM7, VVM14 orVVM30) or a future VVM type approved by WHO(WHO/V&B/99.187, WHO/IVB/07.048).

- Signed declaration, as part of the cover letter submitted along with the file for prequalification confirming that the manufacturer will apply a VVM to the vaccine, and has the technical capacity to do so if requested by the purchasing specifications.



WHO Guidelines on Stability Evaluation of Vaccines¹

The temperature sensitivity of vaccine characteristics, particularly potency, has a major impact on the success of global immunization programmes. WHO has acknowledged the importance of clearly defining the stability characteristics of a vaccine.

Chapter 10. Labeling states:

"If Vaccine Vial Monitors (VVM) are to be used, adequate stability data should be generated to support selection of appropriate VVM for a vaccine in question. Further details on the use of VVM for different types of products are available elsewhere."²



WHO/BS/06.2049 - Final ENGLISH ONLY

GUIDELINES ON STABILITY EVALUATION OF VACCINES

© World Health Organization 2006

All rights reserved. Publications of the World Health Organization can be obtained from WHO Preas, World Health Organization, 20 Avenue Appis, 1211 Geneva 27, Switzerland (tdi.: +41 12 791 3264, (ac: +41 22 791 4875, semail: <u>bookcorders@twho.int</u>). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution –-should be addressed to WHO Preas, at the above address (fas: +41 22 791 4806; c-mail: permission@twho.inf).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its suthorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not y do be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are enforced or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. The named authors [editors] alone are responsible for the view expressed in this publication.

Adopted by the 57th meeting of the WHO Expert Committee on Biological Standardization, 23-27 October 2006. A definitive version of this document, which will differ from this version in editorial but not actentific descili, will be published in the WHO Textucial Report Series.

1 http://www.who.int/biologicals/publications/trs/areas/vaccines/stability/Microsoft%20Word%20-%20BS%202049.Stability.final.09_Nov_06.pdf


²WHO *Temperature Sensitivity of Vaccines* (WHO/IVB/06.10)



12

WHO Temperature Sensitivity of Vaccines³


- The basis for choosing a VVM category for a given vaccine is the Accelerated Degradation Test (ADT).
- In this test samples are subjected to a range of elevated temperatures at which significant and readily detectable degradation is induced in a relatively short time. The rate at which degradation occurs is measured and analyzed in accordance with the Arrhenius equation.
- Vaccines should be tested to failure at these accelerated temperatures.
- Vaccines do not need to follow the Arrhenius equation exactly to have a suitable VVM applied.



³http://www.who.int/vaccines-documents/DocsPDF06/847.pdf

VVM Characteristics

VVM is a WHO prequalified device



Temperature Intelligence[®] Solutions

WHO PQS Performance Specification: Vaccine Vial Monitor (WHO/PQS/E06/IN05)⁵

VVM reaction rates

(new categories to be added: VVM11 and VVM250)


Category (Vaccines)	No. of days to end point at +37°C	No. of days to end point at +25°C	Time to end point at +5°C
VVM 30: High Stability	30	193	>4 years
VVM 14: Medium Stability	14	90	>3 years
VVM 7: Moderate Stability	7	45	>2 years
VVM 30: Least Stable	2	N/A*	225 days

The four categories of VVM are VVM2, VVM7, VVM14 and VVM30

⁵http://www.who.int/immunization_standards/vaccine_quality/who_pqs_e06_in05_1.pdf



Arrhenius Graph of VVM Categories Based on Upper Limits at 25°C and 37°C



DAYS

Selection of VVM Category Example: Product A

Step 1: Summarize stability data

- 2 to 8°C¹: 3 years (1095 days)
- 25°C: 45 days
- 37°C: 7 days
- Expiry Date: 2 years


¹2 to 8°C is treated as 5°C





Product A Stability Data and VVM Categories

Step 2: Compare stability data with VVM categories



Temperature Intelligence[™] Solutions

Temptime Improving Global Health

Product A VVM Choice and Rationale

100000 10000 VVM14 and VVM30 – Reach End **Point After Vaccine is Sub-potent** 1000 100 VVM2 – Reaches End **Point Too Fast** 10 -1 0 10 15 20 25 30 35 37 40 5 **Degrees C** - VVM30 ---- VVM14 ---- VVM7 -VVM2 19

Step 2: Compare stability data with VVM categories

DAYS

Temperature Intelligence[™] Solutions

Temptime[®] Improving Global Health

Selection of VVM Category Example: Product B

Step 1: Summarize stability data

- 2 to 8°C¹: 1600 days
- 25°C: 150 days
- 37°C: 21 years
- Expiry Date: 2 years

¹2 to 8°C is treated as 5°C






Temptime*
Improving Global Health


Product B Stability Data and VVM Categories

Step 2: Compare stability data with VVM categories





Other HEATmarker TTI Categories



HEATmarkers with UV Protection

Temperature Intelligence[™] Solutions



M

Thank you!!!



2

Temperature Intelligence[™] Solutions